Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment

Oral Diseases

Volumn 17, Issue 4, 2011, Pages 433-442

  Wehrhan, F ^a   Hyckel, P ^b   Amann, K ^a   Ries, J ^a   Stockmann, P ^a   Schlegel, Ka ^a   Neukam, Fw ^a   Nkenke, E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Aminobisphosphonate; Bone; Jaw; Msx 1; ONJ

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN 2; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR MSX1;

ARTICLE; BONE TURNOVER; CELL LABELING; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAW OSTEONECROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ALKALINE PHOSPHATASE; BONE DENSITY CONSERVATION AGENTS; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE REMODELING; CELL COUNT; DIPHOSPHONATES; FIBROBLASTS; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; JAW DISEASES; MSX1 TRANSCRIPTION FACTOR; OSTEOBLASTS; OSTEOCYTES; OSTEONECROSIS; OSTEOPETROSIS; RANK LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 79953763072     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2010.01778.x     Document Type: Article

References (60)

1. Abu-Id MH, Warnke PH, Gottschalk J et al (2008). "Bis-phossy jaws"- high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 36: 95-103.
2. Agarwala S, Sule A, Pai BU, Joshi VR (2002). Alendronate in the treatment of avascular necrosis of the hip. Rheumatology (Oxford) 41: 346-347.
3. Aioub M, Lezot F, Molla M et al (2007). Msx2 -/- transgenic mice develop compound amelogenesis imperfecta, dentinogenesis imperfecta and periodental osteopetrosis. Bone 41: 851-859.
4. Amanat N, McDonald M, Godfrey C, Bilston L, Little D (2007). Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res 22: 867-876.
5. Babajko S, Petit S, Fernandes I et al (2009). Msx1 expression regulation by its own antisense RNA: consequence on tooth development and bone regeneration. Cells Tissues Organs 189: 115-121.
6. Barry CP, Ryan CD (2003). Osteomyelitis of the maxilla secondary to osteopetrosis: report of a case. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95: 12-15.
7. Belibasakis GN, Bostanci N, Hashim A et al (2007). Regulation of RANKL and OPG gene expression in human gingival fibroblasts and periodontal ligament cells by Porphyromonas gingivalis: a putative role of the Arg-gingipains. Microb Pathog 43: 46-53.
8. Berdal A, Molla M, Hotton D et al (2009). Differential impact of MSX1 and MSX2 homeogenes on mouse maxillofacial skeleton. Cells Tissues Organs 189: 126-132.
9. Bisdas S, Chambron Pinho N, Smolarz A, Sader R, Vogl TJ, Mack MG (2008). Biphosphonate-induced osteonecrosis of the jaws: CT and MRI spectrum of findings in 32 patients. Clin Radiol 63: 71-77.
10. Blin-Wakkach C, Lezot F, Ghoul-Mazgar S et al (2001). Endogenous Msx1 antisense transcript: in vivo and in vitro evidences, structure, and potential involvement in skeleton development in mammals. Proc Natl Acad Sci USA 98: 7336-7341.
11. Chung IH, Yamaza T, Zhao H, Choung PH, Shi S, Chai Y (2009). Stem cell property of postmigratory cranial neural crest cells and their utility in alveolar bone regeneration and tooth development. Stem Cells 27: 866-877.
12. Cohen MM Jr (2006). The new bone biology: pathologic, molecular, and clinical correlates. Am J Med Genet 140: 2646-2706.
13. Dodig M, Kronenberg MS, Bedalov A et al (1996). Identification of a TAAT-containing motif required for high level expression of the COL1A1 promoter in differentiated osteoblasts of transgenic mice. J Biol Chem 271: 16422-16429.
14. Favia G, Pilolli GP, Maiorano E (2009). Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone 45: 406-413.
15. Gersch RP, Lombardo F, McGovern SC, Hadjiargyrou M (2005). Reactivation of Hox gene expression during bone regeneration. J Orthop Res 23: 882-890.
16. Hansen T, Kunkel M, Kirkpatrick CJ, Weber A (2006a). Actinomyces in infected osteoradionecrosis - underestimated? Hum Pathol 37: 61-67.
17. Hansen T, Kunkel M, Weber A, James Kirkpatrick C (2006b). Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35: 155-160.
18. Henry D, vonMoos R, Vadhan-Raj S et al (2009). A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Eur J Can Suppl 7: 11, Abstract 20LBA.
19. Hoffmann HM, Catron KM, van Wijnen AJ et al (1994). Transcriptional control of the tissue-specific, developmentally regulated osteocalcin gene requires a binding motif for the Msx family of homeodomain proteins. Proc Natl Acad Sci USA 91: 12887-12891.
20. Houpis CH, Tosios KI, Papavasileiou D et al (2010). Parathyroid hormone-related peptide (PTHrP), parathyroid hormone/parathyroid hormone-related peptide receptor 1 (PTHR1), and MSX1 protein are expressed in central and peripheral giant cell granulomas of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 109: 415-424.
21. Hyckel P, Berndt A, Schleier P et al (2005). Cherubism - new hypotheses on pathogenesis and therapeutic consequences. J Craniomaxillofac Surg 33: 61-68.
22. Idowu BD, Thomas G, Frow R, Diss TC, Flanagan AM (2008). Mutations in SH3BP2, the cherubism gene, were not detected in central or peripheral giant cell tumours of the jaw. Br J Oral Maxillofac Surg 46: 229-230.
23. Ishii M, Han J, Yen HY, Sucov HM, Chai Y, Maxson RE Jr (2005). Combined deficiencies of Msx1 and Msx2 cause impaired patterning and survival of the cranial neural crest. Development 132: 4937-4950.
24. Khosla S, Burr D, Cauley J et al (2007). Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22: 1479-1491.
25. Lekic P, Rubbino I, Krasnoshtein F, Cheifetz S, McCulloch CA, Tenenbaum H (1997). Bisphosphonate modulates proliferation and differentiation of rat periodontal ligament cells during wound healing. Anat Rec 247: 329-340.
26. Lesclous P (2009). Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? Bone 45: 843-852.
27. Leucht P, Kim JB, Amasha R, James AW, Girod S, Helms JA (2008). Embryonic origin and Hox status determine progenitor cell fate during adult bone regeneration. Development 135: 2845-2854.
28. Lezot F, Coudert A, Petit S et al (2004). Does Vitamin D play a role on Msx1 homeoprotein expression involving an endogenous antisense mRNA? J Steroid Biochem Mol Biol 89-90: 413-417.
29. Marx RE (2003). Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61: 1115-1117.
30. Marx RE, Sawatari Y, Fortin M, Broumand V (2005). Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63: 1567-1575.
31. Matos MA, Araujo FP, Paixao FB (2007). The effect of zoledronate on bone remodeling during the healing process. Acta Cir Bras 22: 115-119.
32. Matsubara T, Suardita K, Ishii M et al (2005). Alveolar bone marrow as a cell source for regenerative medicine: differences between alveolar and iliac bone marrow stromal cells. J Bone Miner Res 20: 399-409.
33. Maxson R, Ishii M (2008). The Bmp pathway in skull vault development. Front Oral Biol 12: 197-208.
34. Menezes AM, Rocha FA, Chaves HV, Carvalho CB, Ribeiro RA, Brito GA (2005). Effect of sodium alendronate on alveolar bone resorption in experimental periodontitis in rats. J Periodontol 76: 1901-1909.
35. Miah SM, Hatani T, Qu X, Yamamura H, Sada K (2004). Point mutations of 3BP2 identified in human-inherited disease cherubism result in the loss of function. Genes Cells 9: 993-1004.
36. Newberry EP, Boudreaux JM, Towler DA (1997). Stimulus-selective inhibition of rat osteocalcin promoter induction and protein-DNA interactions by the homeodomain repressor Msx2. J Biol Chem 272: 29607-29613.
37. Nishida S, Kikuichi S, Haga H et al (2003). Apoptosis-inducing effect of a new bisphosphonate, YM529, on various hematopoietic tumor cell lines. Biol Pharm Bull 26: 96-100.
38. Nishida S, Tsubaki M, Hoshino M et al (2005). Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2. Biochem Biophys Res Commun 328: 91-97.
39. Orestes-Cardoso SM, Nefussi JR, Hotton D et al (2001). Postnatal Msx1 expression pattern in craniofacial, axial, and appendicular skeleton of transgenic mice from the first week until the second year. Dev Dyn 221: 1-13.
40. Orestes-Cardoso S, Nefussi JR, Lezot F et al (2002). Msx1 is a regulator of bone formation during development and postnatal growth: in vivo investigations in a transgenic mouse model. Connect Tissue Res 43: 153-160.
41. Reddy GT, Kumar TM, Veena KM (2005). Formulation and evaluation of Alendronate Sodium gel for the treatment of bone resorptive lesions in Periodontitis. Drug Deliv 12: 217-222.
42. Reid IR (2009). Osteonecrosis of the jaw: who gets it, and why? Bone 44: 4-10.
43. Roybal PG, Wu NL, Sun J, Ting MC, Schafer CA, Maxson RE (2010). Inactivation of Msx1 and Msx2 in neural crest reveals an unexpected role in suppressing heterotopic bone formation in the head. Dev Biol 343: 28-39.
44. Ruhin-Poncet B, Ghoul-Mazgar S, Hotton D et al (2009). Msx and dlx homeogene expression in epithelial odontogenic tumors. J Histochem Cytochem 57: 69-78.
45. Ryoo HM, Hoffmann HM, Beumer T et al (1997). Stage-specific expression of Dlx-5 during osteoblast differentiation: involvement in regulation of osteocalcin gene expression. Mol Endocrinol 11: 1681-1694.
46. Schwabe UZR (2005). Mineralstoffpräparate und OSteoporosemittel. In: Schwabe U, Paffrath D, eds. Arzneiverordnungsreport 2005. Springer: Berlin, Heidelberg, pp. 755-756.
47. Senel FC, Duman MK, Muci E et al (2010). Jaw bone changes in rats after treatment with zoledronate and pamidronate. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 109: 385-391.
48. Shirakabe K, Terasawa K, Miyama K, Shibuya H, Nishida E (2001). Regulation of the activity of the transcription factor Runx2 by two homeobox proteins, Msx2 and Dlx5. Genes Cells 6: 851-856.
49. Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever PG (2006). Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci 119: 1283-1296.
50. Stefanik D, Sarin J, Lam T, Levin L, Leboy PS, Akintoye SO (2008). Disparate osteogenic response of mandible and iliac crest bone marrow stromal cells to pamidronate. Oral Dis 14: 465-471.
51. Stockmann P, Vairaktaris E, Wehrhan F et al (2010). Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12months follow-up. Support Care Cancer 18: 449-460.
52. Stopeck A, Body J, Fujiwara Y et al (2009). Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: rusults of a randomized phase 3 study. Eur J Can Suppl 7: 2LBA.
53. Taylor KH, Middlefell LS, Mizen KD (2010). Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg 48: 221-223.
54. Teot LA, O'Keefe RJ, Rosier RN, O'Connell JX, Fox EJ, Hicks DG (1996). Extraosseous primary and recurrent giant cell tumors: transforming growth factor-beta1 and -beta2 expression may explain metaplastic bone formation. Hum Pathol 27: 625-632.
55. Tsubaki M, Kato C, Nishinobo M et al (2008). Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits macrophage inflammatory protein 1 alpha expression and secretion in mouse myeloma cells. Cancer Sci 99: 152-158.
56. Ueki Y, Tiziani V, Santanna C et al (2001). Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Nat Genet 28: 125-126.
57. Viereck V, Emons G, Lauck V et al (2002). Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291: 680-686.
58. Weibel ER (1989). Measuring through the microscope: development and evolution of stereological methods. J Microsc 155: 393-403.
59. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S (2003). Bisphosphonate-induced osteopetrosis. N Engl J Med 349: 457-463.
60. Whyte MP, McAlister WH, Novack DV, Clements KL, Schoenecker PL, Wenkert D (2008). Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases. J Bone Miner Res 23: 1698-1707.